{"id":453497,"date":"2021-03-09T07:33:14","date_gmt":"2021-03-09T12:33:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=453497"},"modified":"2021-03-09T07:33:14","modified_gmt":"2021-03-09T12:33:14","slug":"tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/","title":{"rendered":"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences"},"content":{"rendered":"
\n

CHATHAM, N.J., March 09, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the following upcoming virtual investor conferences.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
Event<\/td>\n33rd<\/sup> Annual ROTH Conference<\/td>\n<\/tr>\n
Date<\/td>\nMarch 16, 2021<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Event<\/td>\nMaxim Emerging Growth Conference<\/td>\n<\/tr>\n
Date<\/td>\nMarch 17-18, 2021<\/td>\n<\/tr>\n
Presentation<\/td>\nAvailable on demand beginning March 17<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Event<\/td>\nInvestor Summit<\/td>\n<\/tr>\n
Date<\/td>\nMarch 23-25, 2021<\/td>\n<\/tr>\n
Presentation<\/td>\nMarch 23 at 10:30 a.m. ET<\/td>\n<\/tr>\n<\/table>\n

Webcasts of the Maxim and Investor Summit conferences presentations will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com<\/a>.<\/p>\n

\n Tonix Pharmaceuticals Holding Corp. <\/strong>\n <\/p>\n

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix\u2019s portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix\u2019s lead CNS candidate, TNX-102 SL1<\/sup>, is in mid-Phase 3 development for the management of fibromyalgia, and positive data on the RELIEF Phase 3 trial were recently reported. The Company expects interim data from a second Phase 3 study, RALLY, in the third quarter of 20212<\/sup> and topline data in the fourth quarter of 2021. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer, and autoimmune diseases. Tonix\u2019s lead vaccine candidate, TNX-18003<\/sup>, is a live replicating vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response. Tonix expects efficacy data from animal studies of TNX-1800 in the first quarter of 2021. TNX-8013<\/sup>, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox.<\/p>\n

\n 1<\/sup>TNX-102 SL is an investigational new drug and has not been approved for any indication.
2<\/sup>Pending submission and agreement from FDA on statistical analysis plan.
3<\/sup>TNX-1800 and TNX-801 are investigational new biologics and have not been approved for any indication.<\/p>\n

This press release and further information about Tonix can be found at www.tonixpharma.com.<\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201cforecast,\u201d \u201cestimate,\u201d \u201cexpect,\u201d and \u201cintend,\u201d among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on March 24, 2020, and periodic reports filed with the SEC on or after the date thereof. All Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.<\/p>\n

\n Contacts<\/strong>\n <\/p>\n

Jessica Morris (corporate)
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182<\/p>\n

Olipriya Das, Ph.D. (media)
Russo Partners
Olipriya.Das@russopartnersllc.com
(646) 942-5588<\/p>\n

Peter Vozzo (investors)
Westwicke
peter.vozzo@westwicke.com
(443) 213-0505<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CHATHAM, N.J., March 09, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the following upcoming virtual investor conferences. Event 33rd Annual ROTH Conference Date March 16, 2021 \u00a0 \u00a0 Event Maxim Emerging Growth Conference Date March 17-18, 2021 Presentation Available on demand beginning March 17 \u00a0 \u00a0 Event Investor Summit Date March 23-25, 2021 Presentation March 23 at 10:30 a.m. ET Webcasts of the Maxim and Investor Summit conferences presentations will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals Holding Corp. Tonix is … <\/p>\n

Continue reading “Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-453497","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTonix Pharmaceuticals to Participate in Upcoming March Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CHATHAM, N.J., March 09, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the following upcoming virtual investor conferences. Event 33rd Annual ROTH Conference Date March 16, 2021 \u00a0 \u00a0 Event Maxim Emerging Growth Conference Date March 17-18, 2021 Presentation Available on demand beginning March 17 \u00a0 \u00a0 Event Investor Summit Date March 23-25, 2021 Presentation March 23 at 10:30 a.m. ET Webcasts of the Maxim and Investor Summit conferences presentations will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals Holding Corp. Tonix is … Continue reading "Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T12:33:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences\",\"datePublished\":\"2021-03-09T12:33:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/\"},\"wordCount\":654,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/\",\"name\":\"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=\",\"datePublished\":\"2021-03-09T12:33:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences - Market Newsdesk","og_description":"CHATHAM, N.J., March 09, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will participate in the following upcoming virtual investor conferences. Event 33rd Annual ROTH Conference Date March 16, 2021 \u00a0 \u00a0 Event Maxim Emerging Growth Conference Date March 17-18, 2021 Presentation Available on demand beginning March 17 \u00a0 \u00a0 Event Investor Summit Date March 23-25, 2021 Presentation March 23 at 10:30 a.m. ET Webcasts of the Maxim and Investor Summit conferences presentations will be available under the IR Events tab of the Investors section of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals Holding Corp. Tonix is … Continue reading \"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T12:33:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences","datePublished":"2021-03-09T12:33:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/"},"wordCount":654,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/","name":"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=","datePublished":"2021-03-09T12:33:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NjYyNiM0MDU0NDUxIzIwMTExMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tonix-pharmaceuticals-to-participate-in-upcoming-march-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tonix Pharmaceuticals to Participate in Upcoming March Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453497","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=453497"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/453497\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=453497"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=453497"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=453497"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}